Related by context. All words. (Click for frequent words.) 74 antibody titer 74 Engerix B 74 hemagglutination inhibition 74 seroconversion 73 antibody titers 71 mcg dose 71 complete cytogenetic response 71 HI titers 70 CCyR 69 seropositivity 69 serum antibody 68 tipranavir r 68 HBeAg seroconversion 68 sustained virological response 68 definite stent thrombosis 68 seroprotective 68 titers 68 ACR# response 68 virologic responses 68 sustained virologic response 68 evaluable subjects 67 PASI scores 67 relapsed MM 67 CR nPR 67 virologic failure 67 virological response 67 mg kg dose 67 log# reduction 67 viral kinetics 67 imipenem 66 #mg dose [002] 66 trivalent inactivated influenza 66 hemagglutination inhibition HAI 66 microg 66 HAI titers 66 MF# adjuvanted 66 ACR# responses 66 DAS# remission 66 achieved ACR# 66 hepatitis C genotype 66 MCyR 66 virologic suppression 66 SCIg 66 oral allopurinol 66 Menveo 66 CANCIDAS 66 complete cytogenetic 66 amoxicillin clavulanate 65 BARACLUDE ® 65 inactivated influenza vaccine 65 BCG vaccinated 65 pCR 65 severe rotavirus gastroenteritis 65 -#.# log# copies mL 65 anti HBs 65 virologic response 65 intramuscular dose 65 transaminase elevations 65 hours postdose 65 Solid Tumors criteria 65 desvenlafaxine succinate 65 sUA 65 reactogenicity 65 undetectable HBV DNA 65 HCV genotype 65 pegylated interferon alfa 65 dose cohort 65 antiviral efficacy 65 methotrexate monotherapy 65 HPV-#/# 65 REYATAZ r arm 64 APTIVUS r 64 mg/m2 dose 64 antibody responses 64 HIV RNA 64 elevated ALT 64 clinically meaningful improvement 64 seroconverted 64 μg dose 64 NNRTI resistance 64 mIU mL 64 #mg/day [001] 64 8mg/kg 64 mg ustekinumab 64 mcg BID 64 certolizumab 64 Viral load 64 fluticasone salmeterol 64 quadrivalent HPV vaccine 64 microgram dose 64 PPSV# 64 EDSS score 64 LEXIVA r 64 steroid dexamethasone 64 palivizumab 64 leukocyte count 64 pneumococcal vaccination 64 PREZISTA r 64 mcg mL 64 mcg albinterferon alfa 2b 64 heavily pretreated 64 achieved CCyR 64 dapagliflozin plus 64 Immunogenicity 64 fosamprenavir 64 serum urate 64 CAIV T 63 HER2 expression 63 serum concentrations 63 alanine aminotransferase ALT 63 #mg BID [001] 63 HBeAg negative patients 63 anemia hemoglobin 63 % Confidence Interval 63 chronic HBV 63 inactivated poliovirus vaccine 63 HBeAg positive patients 63 posaconazole 63 noninferiority 63 μmol L 63 serum urate levels 63 plasma HCV RNA 63 LC#m# 63 hemoglobin concentrations 63 micafungin 63 CIMZIA TM 63 median survivals 63 peginterferon alfa 2a #KD 63 SVR# 63 protease inhibitor PI 63 chlorambucil 63 HbA 1c levels 63 response CCyR 63 lopinavir 63 4CMenB 63 Non inferiority 63 HBeAg 63 HIV HCV coinfected 63 Baseline characteristics 63 RSV hospitalizations 63 mg BID dose 63 microbiological eradication 63 valent pneumococcal conjugate vaccine 63 genotypic resistance 63 genotype 1b 63 abacavir lamivudine 63 ertapenem 63 mg QD 63 baseline HbA1c 63 virologic 63 antiretroviral naive 63 HIV uninfected 63 undetectable viral 63 lopinavir r arm 63 ALT flares 63 dose Iluvien 63 alanine aminotransferase 63 external genital lesions 63 darunavir r 63 experienced virologic failure 63 fluvastatin 63 NPH insulin 63 lumbar spine BMD 63 adalimumab 63 undetectable viral load 63 NNRTI resistant virus 63 FluCAM 63 FFNS 63 plus dexamethasone 63 mg eq 63 % CI #.#-#.# [003] 63 Aptivus ® 63 plus COPEGUS 63 Immune responses 63 CMV infection 63 plus methotrexate 63 MenACWY CRM 62 HBeAg positive 62 tigecycline 62 pegylated interferon alpha 62 daunorubicin 62 trivalent influenza vaccine 62 interferon alfa 2b 62 hsCRP levels 62 MenACWY 62 rapid virologic response 62 glycated hemoglobin levels 62 lymphocytosis 62 Pharmacokinetic parameters 62 dosing cohort 62 #mg/day [002] 62 Hb A1C 62 Flu Cy 62 non adjuvanted vaccines 62 IOP lowering 62 ACTEMRA TM 62 highly immunogenic 62 quadrivalent vaccine 62 progression TTP 62 LPV r 62 neutralizing antibody 62 CR CRu 62 seronegative 62 piperacillin tazobactam 62 monoinfected patients 62 pharmacokinetic characteristics 62 Peg IFN 62 PSA nadir 62 dose proportionality 62 azilsartan medoxomil 62 HIV coinfected 62 locoregional disease 62 neutrophil counts 62 ritonavir boosted 62 Cethromycin 62 seropositive patients 62 Havrix 62 cEVR 62 #mg BID [002] 62 comparator arm 62 radezolid 62 IgG antibody 62 clodronate 62 statistical significance p 62 binary restenosis 62 tapentadol ER 62 Doxil ® 62 achieved sustained virological 62 bactericidal activity 62 MAS XR 62 complete remissions 62 aged ≥ 62 Raptiva r 62 expressors 62 atazanavir ritonavir 62 octreotide LAR 62 CIMZIA ™ 62 cefepime 62 MF# adjuvanted vaccine 62 nonvaccine serotypes 62 alteplase 62 telbivudine 62 titer 62 #mg BID [003] 62 FluCAM arm 62 viraemia 61 aspartate aminotransferase 61 CIN3 61 3mg/kg 61 mCi kg 61 postintervention 61 chronic HCV genotype 61 TLUS 61 annualized relapse 61 q8h 61 antibody titres 61 TYGACIL 61 biochemical relapse 61 ribavirin RBV 61 doripenem 61 indinavir 61 lopinavir r 61 EDSS scores 61 patients evaluable 61 antiretroviral naïve 61 pegylated alpha interferon 61 inecalcitol 61 STELARA ® 61 NRTI resistance 61 achieved statistical significance 61 plasma cortisol 61 mg BID 61 maximally tolerated dose 61 oxycodone CR 61 MIC# [001] 61 peginterferon alfa 2a 61 prospectively defined 61 morphometric vertebral fractures 61 DAS# CRP 61 HCV genotypes 61 microgram doses 61 tipranavir ritonavir 61 weekly subcutaneous injections 61 Scale EDSS 61 #OHD levels 61 ARB telmisartan 61 nonnucleoside reverse transcriptase inhibitors 61 virological failure 61 valacyclovir 61 mIU ml 61 ARCOXIA 61 Cmax 61 caspofungin 61 rapid virological response 61 HBV infections 61 GAMMAGARD 61 ALT elevation 61 intradermal injection 61 HBsAg 61 MAGE A3 ASCI 61 PEG IFN 61 -#.# log# 61 Telbivudine 61 venlafaxine XR 61 mcg QD 61 mg TID 61 oral FTY# 61 Subgroup analyzes 61 moderate renal impairment 61 serum ALT 61 vaccinees 61 #ug [002] 61 teriflunomide 61 sUA levels 61 insulin detemir 61 DAS# scores 61 A1c levels 61 advanced adenoma 61 troponin T 61 cotrimoxazole 61 baseline LDH 61 peginterferon alfa 2b 61 INVEGA ® 61 HbA1C 61 resected pancreatic cancer 61 plasma folate 61 CC genotype 61 HEPLISAV 61 statin monotherapy 61 undetectable viral loads 61 urate lowering therapy 61 preintervention 61 virological suppression 61 Kaplan Meier estimate 61 #q# deletion syndrome 61 DLTs 61 Altastaph 61 IU ml 61 nucleoside naive patients 61 serum aminotransferase levels 61 polysaccharide vaccine 61 baseline A1C 61 eosinophilic asthma 61 low dose Iluvien 60 platelet reactivity 60 vaccine serotypes 60 TMC# r 60 KRAS mutations occur 60 transaminases 60 Kaplan Meier analysis 60 peginterferon alpha 2a 60 LTBI 60 vaginal progesterone gel 60 RECIST Response Evaluation Criteria 60 HBV vaccine 60 cytogenetic response 60 HBV DNA levels 60 doxorubicin docetaxel 60 #mg doses [002] 60 microbiologically evaluable 60 MCV4 60 Fluzone Intradermal vaccine 60 serum IGF 60 salmeterol fluticasone 60 gemcitabine carboplatin 60 #mg/kg [002] 60 mg Proellex 60 otamixaban 60 alfa 2a 60 serum phosphate 60 recurrent genital herpes 60 pegylated interferon alfa 2b 60 galiximab 60 viral suppression 60 timepoints 60 postexposure 60 coinfected 60 treatment naive genotype 60 virologically 60 lymphocyte count 60 low dose cytarabine 60 adenoma recurrence 60 histologically confirmed 60 lanthanum carbonate 60 trivalent vaccine 60 serum lipid levels 60 intraocular inflammation 60 DOXIL 60 CMV disease 60 log# 60 XIENCE V PROMUS Stent 60 receiving INTRON 60 ACR Pedi 60 ribavirin therapy 60 serum testosterone 60 mRCC 60 Virologic 60 tipranavir 60 PPSV 60 % CI #.#-#.# [007] 60 pneumococcal infection 60 plasma pharmacokinetics 60 INCB# [003] 60 pyrazinamide 60 iPTH 60 null responder 60 ALT normalization 60 BENICAR HCT 60 null responders 60 chronic HCV infection 60 pegIFN 60 poor metabolizers 60 μg dL 60 CERVARIX 60 LC#m# vaccine 60 transaminase levels 60 mcg Albuferon 60 TPV r 60 #μg [001] 60 Pegasys ® 60 viremia 60 dose cytarabine 60 ascending dose 60 K ras mutations 60 peginterferon 60 decitabine 60 ROTATEQ 60 pharmacodynamic PD 60 treatment naïve genotype 60 RoACTEMRA 60 PCV# 60 maximal tolerated 60 Virologic failure 60 concomitant antibiotics 60 Heplisav 60 peg IFN 60 oral diclofenac 60 invasive aspergillosis 60 Lupuzor ™ 60 unformulated vaccine 60 hepatitis B immunoglobulin 60 Median survival 60 hemoglobin A1c HbA1c 60 metastatic RCC 60 viral titers 60 ug kg 60 low expressors 60 COPEGUS 60 adefovir 60 de novo AML 60 HbA1C levels 60 autoantibody positive 60 #.#mg/dL 60 undetectable hepatitis C 60 detectable HCV RNA 60 Platelet counts 60 Ad5 60 R# #mg BID 60 ARCALYST ® 60 mcg doses 60 Index CDAI 60 dose cohorts 60 statistically significant p = 60 μg kg 60 Ixiaro 60 MADRS score 60 retapamulin 60 stavudine d4T 60 rizatriptan 60 daily subcutaneous injections 60 Crohn Disease Activity 60 APTIVUS R 60 μg L 60 ritonavir boosted lopinavir 60 Kinoid 60 #mg dose [001] 60 High Dose quadruples 60 fasting plasma glucose FPG 60 idraparinux 60 serum clusterin levels 60 KRAS status 60 nilotinib 59 PegIFN RBV 59 humoral responses 59 decompensated liver disease 59 nelfinavir 59 canakinumab 59 hA# 59 pharmacokinetic equivalence 59 EURIDIS 59 dosing cohorts 59 virologic breakthrough 59 saline placebo 59 NOAEL 59 rFSH 59 serum potassium 59 hematologic toxicity 59 VELCADE melphalan 59 RECIST criteria 59 potent antiretroviral therapy 59 tacrolimus ointment 59 plasma leptin 59 Virulizin ® 59 ceftazidime 59 FOLPI 59 CTAP# Capsules 59 remission CR 59 achieved sustained virologic 59 lispro 59 #mg QD [002] 59 ceftriaxone 59 prospectively stratified 59 evaluating tivozanib 59 nondiabetic patients 59 HIV seronegative 59 HBeAg negative 59 serum uric acid 59 PCV7 vaccine 59 active comparator 59 mg/m2 cohort 59 RAPTIVA 59 reduce serum phosphate 59 Folfox 59 linaclotide treated 59 postexposure prophylaxis 59 Pegasys peginterferon alfa 2a 59 macrolide antibiotic 59 levetiracetam 59 IFN beta 59 antiviral activity 59 peginterferon alfa 59 ipsilateral stroke 59 bortezomib refractory 59 FOLFOX 59 PREZISTA r arm 59 serologic 59 REYATAZ R 59 Solid Tumors 59 Traficet EN 59 micrograms mL 59 rilpivirine 59 severe neutropenia 59 recurrent VTE 59 serum vitamin D 59 PASI score 59 mg RDEA# 59 alemtuzumab treated 59 AST ALT 59 CRp 59 dalteparin 59 attain statistical significance 59 peripheral blood mononuclear 59 Timed Walk 59 FOLFOX4 59 CD# upregulation 59 varicella vaccine 59 CCR5 tropic HIV 59 dosage regimens 59 tolterodine ER 59 NAbs 59 PENNVAX B 59 specific antigen PSA 59 cART 59 adefovir treated 59 anagrelide 59 candidemia 59 liver histology 59 dose dexamethasone 59 azacitidine 59 low dose ritonavir 59 adjunctive placebo 59 dose statin therapy 59 solifenacin 59 NHANES III 59 GH deficiency 59 immunoglobulin G 59 hemoglobin A1c levels 59 virus HBV 59 YERVOY 59 CHOP chemotherapy 59 S. aureus isolates 59 corticosteroid dose 59 mmol l 59 serogroup B 59 locoregional recurrence 59 cidofovir 59 dacarbazine chemotherapy 59 Response Evaluation Criteria 59 CK # plasma concentrations 59 HCV genotype 1 59 7 valent pneumococcal 59 lopinavir ritonavir 59 β blockers 59 mesalamine granules 59 biologic DMARD 59 MabCampath 59 #mg q8h 59 TransVax ™ 59 im peramivir 59 MRSA colonization 59 seroprevalence 59 aminotransferase levels 59 GARDASIL ® 59 pimecrolimus cream 59 pegylated IFN 59 tolerability profiles 59 HBeAg + 59 Tarceva TM 59 Kaplan Meier estimates 59 HCV replicon 59 serum creatinine levels 59 alpha 2a 59 placebo dexamethasone 59 undetectable virus HCV 59 Operative mortality 59 Pegylated interferon 59 pegylated interferon alfa 2a 59 visceral metastases 59 elevated LDH 59 antiviral potency 59 divalproex sodium 59 CIMZIA TM certolizumab pegol 59 enfuvirtide 59 NATRECOR R 59 receiving highly emetogenic 59 TDF FTC 59 combination REBETOL PEG 59 varicella vaccines 59 HSCT 59 Scale EDSS score 59 ALT elevations 59 serum folate 59 median CD4 59 nonvaccine 59 Pentacel vaccine 59 latent tuberculosis infection 59 mg/m2/day 59 serum HBV DNA 59 imatinib therapy 59 ribavirin USP 59 p = NS 59 PEG Interferon alfa 59 tocilizumab 59 histologic subtype 59 peg interferon 59 ritonavir boosted atazanavir 59 TT genotype 59 immunocompetent 59 receiving APTIVUS r 59 COPD exacerbation 59 HPV subtypes 59 HbA1c levels 58 abatacept 58 achieved PASI 58 S/GSK# 58 AZT zidovudine Retrovir 58 serum cortisol 58 Severity Index PASI 58 splenectomized patients 58 Nilotinib 58 antithymocyte globulin 58 insulin lispro 58 ECOG PS 58 lamivudine refractory patients 58 interquartile range 58 symptomatic VTE 58 follicular lymphomas 58 ELISPOT 58 Interferon beta 1b 58 immunized mice 58 Free Survival PFS 58 bendamustine 58 4mg/kg 58 flutamide 58 inactivated vaccine 58 Multimeric 58 adalimumab Humira 58 oxcarbazepine 58 apremilast 58 CD4 lymphocyte count 58 NATRECOR ® 58 SGPT 58 parasitaemia 58 aspartate aminotransferase AST 58 potent antiviral 58 CIN2 + 58 nanomolar 58 NRTI backbone 58 MRSA isolates 58 recurrent UTI 58 vaccine LAIV 58 pomalidomide 58 blood phenylalanine Phe 58 melphalan prednisone 58 specific IgE 58 Hb A1c 58 anti leukemic 58 tuberculin skin testing 58 Resolute DES 58 serogroup 58 Rate ORR 58 μg mL 58 linear pharmacokinetics 58 lymphocyte counts 58 achieving PASI 58 ispinesib administered 58 hemoglobin Hb 58 5-FU/LV 58 KINRIX 58 Plasmodium infection 58 receiving Vectibix monotherapy 58 sipuleucel T 58 Sanofi Pasteur Fluzone 58 posttreatment 58 stage IIIB 58 ascending doses 58 noninferior 58 TEAEs 58 mg kg cohorts 58 intradermal injections 58 acellular pertussis DTaP 58 CD4 + cell 58 Sustained virologic response 58 undetectable HCV RNA 58 glycosylated hemoglobin levels 58 receiving VICTRELIS 58 mcg kg REBETOL 58 mg q#h 58 immunogenicity 58 pharmacodynamic properties 58 cisplatin vinorelbine 58 HDRS 58 CVD mortality 58 ZOSTAVAX 58 GnRH agonist 58 #mg QD [001] 58 mg qd 58 placebo controlled clinical trials 58 UPDRS scores 58 somatostatin analog 58 UGT#A# * 58 IFN α 58 serum estradiol 58 nadolol 58 Myelosuppression 58 AVODART 58 IU mL 58 Secondary endpoints include 58 pegylated liposomal doxorubicin 58 atherothrombotic events 58 Primary endpoints 58 T1DM 58 Ishak fibrosis score 58 rituximab refractory 58 intradermally 58 insulin glulisine 58 mEq L 58 HbA 1c 58 cTnT levels 58 telaprevir dosed 58 mCRC patients 58 #mg/m# [002] 58 confirmed CCyR 58 oral olanzapine 58 incidence ≥ 58 delafloxacin 58 serum phosphorus 58 immunological responses 58 nmol L. 58 LEVAQUIN ® 58 pharmacokinetics PK 58 MMSE scores 58 chlamydial infection 58 entecavir 58 live attenuated influenza 58 gastric pH 58 neutropenic fever 58 H#N# mAbs 58 aminotransferase elevations greater 58 clomipramine 58 stage IIIb IV 58 elevated troponin 58 genotype 1a 58 postvaccination 58 HCV antibody 58 baseline FEV 58 ULORIC 58 thrombocytopenic 58 cinacalcet 58 NNT = 58 APOPTONE 58 MMRV vaccine 58 mg simvastatin 58 albumin excretion 58 adverse reactions incidence 58 KRAS wild 58 mg dose 58 Pegasys plus Copegus 58 Psoriasis Area 58 elevated creatinine 58 efavirenz EFV 58 serologically active SLE 58 dexamethasone Decadron 58 antibiotic prophylaxis 58 infliximab monotherapy 58 IgG isotype 58 apolipoprotein B 58 Expanded Disability Status 58 CD8 T cell 58 grade cervical intraepithelial 58 X ULN 58 Twinrix 58 tenofovir FTC 58 Betaferon ® 58 chronic HCV 58 Ophena TM 58 REYATAZ r 58 URTI 58 hour bronchodilation 58 JANUVIA 58 Diamyd r 58 mutated KRAS 58 STELARA 58 Menactra vaccine 58 intravenous bolus 58 serum IgE 58 median PFS 58 RAPAFLO R 58 serum LDL cholesterol 58 ritonavir boosted protease inhibitor 58 TORISEL 58 odds ratios ORs 58 tirofiban 58 titrated glipizide 58 Live Attenuated Influenza Vaccine 58 neutropaenia 58 antitumor effect 58 INTELENCE 58 paricalcitol 58 FDA defined valvulopathy 58 serogroups 58 glycated hemoglobin HbA1c 58 μg ml 58 FOLFOX6 58 Omacetaxine mepesuccinate 58 serogroup C 58 meningococcal conjugate vaccine 58 glycosylated hemoglobin HbA1c 58 μg doses 58 microgram kg 58 APTIVUS 58 COMBIVIR 58 ADCS CGIC 58 virologic failures 58 vicriviroc 58 intracranial hemorrhage ICH 58 pg ml 58 nitazoxanide 58 FOLFOX4 alone 58 Febrile neutropenia 58 zoledronate 58 tetanus diphtheria acellular pertussis 58 gm dl 58 VaD 58 partial remissions 58 poorly immunogenic 58 salmeterol fluticasone propionate 58 urine albumin 58 serum IgG 58 rimonabant #mg/day 58 Elitek 58 BRCA2 mutation carriers 58 chronic HBV infection 58 discontinuations due 57 non splenectomized 57 IELT 57 samalizumab 57 receiving immunosuppressive therapy 57 microgram mcg 57 mg m² 57 relapsed MCL 57 clinically evaluable patients 57 IFN gamma 57 triglyceride concentrations 57 ABC/3TC 57 CPAP adherence 57 statistically significant correlations 57 adverse reactions occurring 57 neutropenia dehydration dyspnea 57 intranasally administered 57 Influenza vaccination 57 trastuzumab Herceptin ® 57 acromegalic patients 57 Symptom severity 57 serologic testing 57 atorvastatin #mg 57 systemic bioavailability 57 radiographic progression 57 tumor regressions 57 serum calcium levels 57 immune reconstitution 57 #mg dose [003] 57 rilonacept 57 rotavirus gastroenteritis 57 p = #.# [003] 57 heterozygotes 57 invasive candidiasis 57 adecatumumab 57 bicalutamide 57 hydroxyvitamin D levels 57 oral prednisone 57 pT2 57 ug mL 57 HBV DNA 57 #mg/m# [001] 57 clinically evaluable 57 riociguat 57 XIENCE V demonstrated 57 antiandrogens 57 ara C 57 PCV7 57 QT QTc 57 cytogenetic responses 57 coinfected patients 57 meropenem 57 NNRTIs 57 standard chemotherapy regimen 57 Stage IIB 57 Pentacel R 57 recurrent venous thromboembolism 57 varicella chickenpox 57 interferon ribavirin 57 Fludara 57 serum HCV RNA 57 intermittent dosing 57 mITT population 57 postdose 57 unfractionated heparin UFH 57 docetaxel chemotherapy 57 serum phosphorous 57 acellular pertussis vaccine 57 chronic periodontitis 57 gadobutrol 57 nephrotoxicity 57 hyperphenylalaninemia HPA due 57 preventing genital warts 57 recurrent glioblastoma multiforme 57 splenectomized 57 glycated hemoglobin 57 CIN2 57 spontaneous preterm delivery 57 NLX P# 57 phase IIb study 57 evaluable 57 neutralizing antibody titers 57 plus ribavirin 57 PEG Intron 57 #μg [002] 57 paliperidone ER 57 log# copies mL 57 SIV infection 57 elevated serum creatinine 57 BEXXAR Therapeutic Regimen 57 CYPHER Stent 57 PON1 enzyme 57 LAIV 57 fluticasone 57 nonexposed 57 mcg kg 57 glomerular filtration 57 #mg ATC 57 epoetin alpha 57 placebo p = 57 NOXAFIL 57 serum ferritin 57 pharmacokinetic PK profile 57 tenofovir emtricitabine 57 clobazam 57 rotavirus infection 57 cells μL 57 darunavir 57 RRMS patients 57 clinically meaningful differences 57 PegIntron 57 cells uL 57 transdermal estradiol 57 XELOX 57 clinico pathological 57 S. pneumoniae 57 QTcF 57 lymphopenia 57 lamivudine 57 quinolone 57 lactate dehydrogenase LDH 57 colorectal neoplasia 57 mean baseline HbA1c 57 receiving golimumab 57 KRAS mutant tumors 57 placebo controlled trials